• DELIVER

early feasibility study to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic control in type 2 diabetes subjects.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

www.clinicaltrials.gov/ct2/show/NCT04285554

  • NN9535-4533 – Type 2 Diabetes & PAD

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE) – This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04560998

  • GPGN – Type 2 Diabetes

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT) – The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk. 

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04255433?titles=SURPASS-CVOT

  • GPHD – Type 2 Diabetes

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6) – The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04537923?titles=SURPASS-6

  • ITSW – Type 2 Diabetes

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) – This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04605991?titles=LY900014

More Coming Soon